A "screen-and-treat" approach for helicobacter pylori infection: A population-based study in Vammala, Finland

Helicobacter

Volumn 15, Issue 1, 2010, Pages 28-37

  Salomaa Räsänen, Anniina ^a   Kosunen, Timo U ^a   Aromaa, Arpo R J ^b   Knekt, Paul ^b   Sarna, Seppo ^c   Rautelin, Hilpi ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Epidemiology; Helicobacter pylori; Mass screening; Population; Primary health care; Serology

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; TETRACYCLINE;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DYSPEPSIA; EDUCATIONAL STATUS; ERADICATION THERAPY; FEMALE; FINLAND; GASTRITIS; HEALTH PROGRAM; HEALTH SURVEY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOUSEHOLD; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; NONHUMAN; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCREENING; SEROLOGY; SEROPREVALENCE; SMOKING;

ADOLESCENT; ADULT; AGED; FEMALE; FINLAND; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 74349100042     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00727.x     Document Type: Article

References (40)

1. Blaser MJ. Helicobacter pylori persistence; biology and disease. J Clin Invest 2004 113 : 321 333.
2. Mégraud F. Epidemiology of Helicobacter pylori infection. Gastroenterol Clin North Am 1993 22 : 73 88.
3. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 1992 102 : 41 6.
4. Banatvala N, Mayo K, Mégraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis 1993 168 : 219 221.
5. Sipponen P, Kosunen TU, Samloff IM, Heinonen OP, Siurala M. Rate of Helicobacter pylori acquisition among Finnish adults: a fifteen year follow-up. Scand J Gastroenterol 1996 31 : 229 232.
6. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994 35 : 742 745.
7. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan GT. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000 181 : 1359 1363.
8. Koch A, Krause TG, Krogfelt K, Olsen OR, Fischer TK, Melbye M. Seroprevalence and risk factors for Helicobacter pylori infection in Greenlanders. Helicobacter 2005 10 : 433 442.
9. Bures J, Kopacova M, Koupil I, et al. Epidemiology of Helicobacter pylori in the Czech Republic. Helicobacter 2006 11 : 56 65.
10. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, Lohi P, Heinonen OP. Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 1997 119 (1 29 34.
11. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. Anonymous. NIH Consensus Conference. JAMA 1994 272 : 65 69.
12. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 (6 772 781. (Pubitemid 46854190)
13. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. A randomized controlled trial. JAMA 2004 291 : 187 194.
14. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajivama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997 6 (8 639 642.
15. Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007 25 : 805 812.
16. Kosunen TU, Hook-Nikanne J, Salomaa A, Sarna S, Aromaa A, Haahtela T. Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to Helicobacter pylori antibodies. Clin Exp Allergy 2002 32 : 373 378.
17. Perez-Perez GI, Salomaa A, Kosunen TU, Daverman B, Rautelin H, Aromaa A, Knekt P, Blaser MJ. Evidence that cagA+ Helicobacter pylori strains are disappearing more rapidly than cagA- strains. Gut 2002 50 (3 295 298.
18. Oksanen A, Veijola L, Sipponen P, Schauman K-O, Rautelin H. Evaluation of pyloriset screen, a rapid whole-blood diagnostic test for Helicobacter pylori infection. J Clin Microbiol 1998 36 : 955 957.
19. Salomaa-Räsänen A, Kosunen TU, Mattila J, Sarna S, Rautelin H. Age-dependent accuracy of Helicobacter pylori antibody assays in adults with special emphasis on atrophic gastritis. Clin Diagn Lab Immunol 2004 11 : 1185 1188.
20. Rehnberg-Laiho L, Salomaa A, Rautelin H, Koskela P, Sarna S, Kosunen TU. Accelerated decline in Helicobacter pylori seroprevalence rate during the screen and treat project in Vammala, Finland, as demonstrated in 29- to 45-year-old pregnant women. APMIS 2004 112 : 34 8.
21. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997 41 : 8 13.
22. Kosunen TU, Seppälä K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992 339 : 893 895.
23. Herbrink P, van Doorn L. Serological methods for diagnosis of Helicobacter pylori infection and monitoring of eradication therapy. Eur J Clin Microbiol Infect Dis 2000 19 : 164 173.
24. Veijola L, Oksanen A, Löfgren T, Sipponen P, Karvonen A-L, Rautelin H. Comparison of three stool antigen tests in confirming Helicobacter pylori eradication in adults. Scand J Gastroenterol 2005 40 : 395 401. (Pubitemid 40546906)
25. Veijola L, Oksanen A, Linnala A, Sipponen P, Rautelin H. Persisting chronic gastritis and elevated Helicobacter pylori antibodies after successful eradication therapy. Helicobacter 2007 12 : 605 608.
26. Leivo T, Salomaa A, Kosunen TU, Tuominen R, Färkkilä M, Linna M, Sintonen H. Cost-benefit analysis of Helicobacter pylori screening. Health Policy 2004 70 : 85 96.
27. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomized controlled trials: a systematic review. J Clin Epidemiol 1999 52 (12 1143 1156.
28. Lane JA, Harvey RF, Murray LJ, Harvey IM, Donovan JL, Nair P, Egger M. A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population: study design and response rates of the Bristol Helicobacter Project. Control Clin Trials 2002 23 (3 321 332.
29. Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, Richards ID, Dowell AC, Axon AT. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000 355 (9216 1665 1669.
30. Wildner-Christensen M, Møller Hansen J, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterolgy 2003 125 : 372 379.
31. Stone MA, Patel H, Panja KK, Barnett DB, Mayberry JF. Reasons for non-compliance with screening for infection with Helicobacter pylori, in a multi-ethnic community in Leicester, UK. Public Health 1998 112 : 153 156. (Pubitemid 28263545)
32. Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Taiwan Community-Based Integrated Screening Group. Cancer 2004 100 : 1734 1743.
33. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006 11 : 418 424.
34. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomized trails: exclusions and selective participation. Health Serv Res Policy 1999 4 : 112 121.
35. Koivisto TT, Rautelin HI, Voutilainen ME, Niemelä SE, Heikkinen MT, Sipponen PI, Färkkilä MA. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther 2004 19 (9 1009 1017.
36. Färkkilä M, Julkunen R, Niemelä S, Nuutinen H, Kosunen T, Karvonen AL, Kunnamo I, Pikkarainen P. Recommendation for the management of Helicobacter pylori infection (Finnish). Suomen Lääkärilehti 1996 2 : 9 13.
37. Quidelines for the management of Helicobacter pylori infection (Finnish). Suomen gastroenterologiayhdistys ry (Niemelä S, Ashorn M, Färkkilä M, Kujala P, Kunnamo I, Pikkarainen P). Duodecim 2000 116 : 548 560.
38. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005 129 : 1910 1917.
39. Lane JA, Murray LJ, Noble S, Egger M, Harvey IM, Donovan JL, Nair P, Harvey RF. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. BMJ 2006 332 (7535 199 204.
40. Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effect of a community screening for Helicobacter pylori: a 5-year follow-up study. Am J Gastroenterol 2008 103 : 1106 1113.